Vantictumab

N/A

Report date: 2025/08/20 15:39:58

Base Information

Drug NameVantictumab
Drug Alias NameOMP-18R5anti-Fzd7
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionFrizzled receptors antagonistsWnt signalling pathway inhibitors
TargetsFrizzled receptorsFrizzled-2Frizzled-1 +[6] 
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursOsteopetrosis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesOncomed Pharmaceuticals IncBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesMereo BiopharmaAshibio IncOncomed Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsOsteopetrosisCarcinoma, Non-Small-Cell Lung
Inactive IndicationsMetastatic breast cancerSolid tumoursPancreatic Neoplasms

Other Information

ATC CodeN/A
Related LinksKEGG